Faculty
Oncology Division
Alphabetical list (active faculty):   
Melissa M. Berrien-Elliott

Melissa M. Berrien-Elliott, PhD

Assistant Professor

Department of Medicine

Oncology Division

Stem Cell Biology

Research Interests

  • Natural killer cells
  • Translational immunology
  • Cancer immunotherapy

Contact

  • 314-747-1547 (office)
  • 314-362-9333 (fax)
  • Division of Oncology
    Mail Stop 8007-0057-06
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Room 634, Southwest Tower (office)

Peer-reviewed Manuscripts

  • A Novel Fusion Protein Scaffold 18/12/TxM Activates the IL-12, IL-15, and IL-18 Receptors to Induce Human Memory-Like Natural Killer Cells
    Cubitt CC, McClain E, Becker-Hapak M, Foltz JA, Wong P, Wagner JA, Neal CC, Marin ND, Marsala L, Foster M, Schappe T, Soon-Shiong P, Lee J, Berrien-Elliott MM, Fehniger TA
    Mol Ther Oncolytics 2022 Feb 15;24:585-596
  • Hematopoietic Cell Transplantation Donor-Derived Memory-Like NK Cells Functionally Persist After Transfer Into Patients With Leukemia
    Berrien-Elliott MM*, Foltz JA*, Russler-Germain DA*, Neal CC, Tran J, Gang M, Wong P, Fisk B, Cubitt CC, Marin ND, Zhou AY, Jacobs MT, Foster M, Schappe T, McClain E, Kersting-Schadek S, Desai S, Pence P, Becker-Hapak M, Eisele J, Mosior M, Marsala L, Griffith OL, Griffith M, Khan SM, Spencer DH, DiPersio JF, Romee R, Uy GL, Abboud CN, Ghobadi A, Westervelt P, Stockerl-Goldstein K, Schroeder MA, Wan F, Lie WR, Soon-Shiong P, Petti AA, Cashen AF, Fehniger TA (*contributed equally)
    Sci Transl Med 2022 Feb 23;14(633):eabm1375
  • Donor Memory-Like NK Cells Persist and Induce Remissions in Pediatric Patients With Relapsed AML After Transplant
    Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC, Foster M, Schappe T, McClain E, Pence PP, Desai S, Kersting-Schadek S, Wong P, Russler-Germain DA, Fisk B, Lie WR, Eisele J, Hyde S, Bhatt ST, Griffith OL, Griffith M, Petti AA, Cashen AF, Fehniger TA
    Blood 2022 Mar 17;139(11):1670-1683
  • Systemic IL-15 Promotes Allogeneic Cell Rejection in Patients Treated With Natural Killer Cell Adoptive Therapy
    Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs M, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein C, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA
    Blood 2022 Feb 24;139(8):1177-1183
  • Phase 1/Dose Expansion Trial of Brentuximab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ward JP, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, Fischer A, Griffith M, Griffith OL, Fehniger TA, Bartlett NL
    Blood 2022 Mar 31;139(13):1999-2010
  • A Fusion Protein Complex That Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
    Becker-Hapak MK, Shrestha N, McClain E, Dee MJ, Chaturvedi P, Leclerc GM, Marsala LI, Foster M, Schappe T, Tran J, Desai S, Neal CC, Pence P, Wong P, Wagner JA, Russler-Germain DA, Zhu X, Spanoudis CM, Gallo VL, Echeverri CA, Ramirez LL, You L, Egan JO, Rhode PR, Jiao JA, Muniz GJ, Jeng EK, Prendes CA, Sullivan RP, Berrien-Elliott MM, Wong HC, Fehniger TA
    Cancer Immunol Res 2021 Sep;9(9):1071-1087
  • Memory-Like Differentiation Enhances NK Cell Responses to Melanoma
    Marin ND, Krasnick BA, Becker-Hapak M, Conant L, Goedegebuure SP, Berrien-Elliott MM, Robbins KJ, Foltz JA, Foster M, Wong P, Cubitt CC, Tran J, Wetzel CB, Jacobs M, Zhou AY, Russler-Germain D, Marsala L, Schappe T, Fields RC, Fehniger TA
    Clin Cancer Res 2021 Sep 1;27(17):4859-4869
  • Combining AFM13, a Bispecific CD30/CD16 Antibody, With Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-Like Responses Against CD30(+) Malignancies
    Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K
    Clin Cancer Res 2021 Jul 1;27(13):3744-3756
  • Phase I Trial of N-803, an IL15 Receptor Agonist, With Rituximab in Patients With Indolent Non-Hodgkin Lymphoma
    Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA
    Clin Cancer Res 2021 Jun 15;27(12):3339-3350
  • Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations With Response After Adoptive Immunotherapy for Leukemia
    Berrien-Elliott MM*, Cashen AF, Cubitt CC, Neal CC, Wong P, Wagner JA, Foster M, Schappe T, Desai S, McClain E, Becker-Hapak M, Foltz JA, Cooper ML, Jaeger N, Srivatsan SN, Gao F, Romee R, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio J, Fehniger TA* (*co-corresponding author)
    Cancer Discov 2020 Dec;10(12):1854-1871
  • CAR-Modified Memory-Like NK Cells Exhibit Potent Responses to NK-Resistant Lymphomas
    Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila M, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, Kahl BS, Kim MY, Cooper ML, DiPersio JF, Berrien-Elliott MM, Fehniger TA
    Blood 2020 Nov 12;136(20):2308-2318
  • CD56 Regulates Human NK Cell Cytotoxicity Through Pyk2
    Gunesch JT, Dixon AL, Ebrahim TA, Berrien-Elliott MM, Tatineni S, Kumar T, Hegewisch-Solloa E, Fehniger TA, Mace EM
    Elife 2020 Jun 8;9
  • Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity
    Wagner JA, Wong P, Schappe T, Berrien-Elliott MM, Cubitt C, Jaeger N, Lee M, Keppel CR, Marin ND, Foltz JA, Marsala L, Neal CC, Sullivan RP, Schneider SE, Keppel MP, Saucier N, Cooper MA, Fehniger TA
    Cell Rep 2020 Jun 2;31(9):107720
  • Potently Cytotoxic Natural Killer Cells Initially Emerge From Erythro-Myeloid Progenitors During Mammalian Development
    Dege C, Fegan KH, Creamer JP, Berrien-Elliott MM, Luff SA, Kim D, Wagner JA, Kingsley PD, McGrath KE, Fehniger TA, Palis J, Sturgeon CM
    Dev Cell 2020 Apr 20;53(2):229-239
  • Blood Natural Killer Cell Deficiency Reveals an Immunotherapy Strategy for Atopic Dermatitis
    Mack MR, Brestoff JR, Berrien-Elliott MM, Trier AM, Yang TB, McCullen M, Collins PL, Niu H, Bodet ND, Wagner JA, Park E, Xu AZ, Wang F, Chibnall R, Council ML, Heffington C, Kreisel F, Margolis DJ, Sheinbein D, Lovato P, Vivier E, Cella M, Colonna M, Yokoyama WM, Oltz EM, Fehniger TA, Kim BS
    Sci Transl Med 2020 Feb 26;12(532)
  • MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells
    Berrien-Elliott MM, Sun Y, Neal C, Ireland A, Trissal MC, Sullivan RP, Wagner JA, Leong JW, Wong P, Mah-Som AY, Wong TN, Schappe T, Keppel CR, Cortez VS, Stamatiades EG, Li MO, Colonna M, Link DC, French AR, Cooper MA, Wang WL, Boldin MP, Reddy P, Fehniger TA
    Immunity 2019 Sep 17;51(3):479-490
  • miR142 Loss-Of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis
    Trissal MC, Wong TN, Yao JC, Ramaswamy R, Kuo I, Baty J, Sun Y, Jih G, Parikh N, Berrien-Elliott MM, Fehniger TA, Ley TJ, Maillard I, Reddy PR, Link DC
    Cancer Res 2018 Jul 1;78(13):3510-3521
  • First-In-Human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse After Transplantation
    Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS
    Blood 2018 Jun 7;131(23):2515-2527
  • CD56bright NK Cells Exhibit Potent Antitumor Responses Following IL-15 Priming
    Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA
    J Clin Invest 2017 Nov 1;127(11):4042-4058
  • Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcgammaRIIIa-Triggered Responses
    Wagner JA, Berrien-Elliott MM, Rosario M, Leong JW, Jewell BA, Schappe T, Abdel-Latif S, Fehniger TA
    Biol Blood Marrow Transplant 2017 Mar;23(3):398-404
  • Recurrent Somatic Mutations Affecting B-Cell Receptor Signaling Pathway Genes in Follicular Lymphoma
    Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA
    Blood 2017 Jan 26;129(4):473-483
  • miR-223 Regulates the Number and Function of Myeloid-Derived Suppressor Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
    Cantoni C, Cignarella F, Ghezzi L, Mikesell B, Bollman B, Berrien-Elliott MM, Ireland AR, Fehniger TA, Wu GF, Piccio L
    Acta Neuropathol 2017 Jan;133(1):61-77
  • Rescue of Tolerant CD8+ T Cells During Cancer Immunotherapy With IL2:Antibody Complexes
    Klevorn LE, Berrien-Elliott MM, Yuan J, Kuehm LM, Felock GD, Crowe SA, Teague RM
    Cancer Immunol Res 2016 Dec;4(12):1016-1026
  • Cytokine-Induced Memory-Like Natural Killer Cells Exhibit Enhanced Responses Against Myeloid Leukemia
    Romee R*, Rosario M*, Berrien-Elliott MM*, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA (*contributed equally)
    Sci Transl Med 2016 Sep 21;8(357):357ra123
  • MicroRNA-15/16 Antagonizes Myb to Control NK Cell Maturation
    Sullivan RP, Leong JW, Schneider SE, Ireland AR, Berrien-Elliott MM, Singh A, Schappe T, Jewell BA, Sexl V, Fehniger TA
    J Immunol 2015 Sep 15;195(6):2806-17
  • Checkpoint Blockade Immunotherapy Relies on T-Bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
    Berrien-Elliott MM, Yuan J, Swier LE, Jackson SR, Chen CL, Donlin MJ, Teague RM
    Cancer Immunol Res 2015 Feb;3(2):116-24
  • Neuropilin-1 Expression Is Induced on Tolerant Self-Reactive CD8+ T Cells but Is Dispensable for the Tolerant Phenotype
    Jackson SR, Berrien-Elliott M, Yuan J, Hsueh EC, Teague RM
    PLoS One 2014 Oct 24;9(10):e110707
  • Inflammation Programs Self-Reactive CD8+ T Cells to Acquire T-Box-Mediated Effector Function but Does Not Prevent Deletional Tolerance
    Jackson SR, Yuan J, Berrien-Elliott MM, Chen CL, Meyer JM, Donlin MJ, Teague RM
    J Leukoc Biol 2014 Sep;96(3):397-410
  • CD8+ T Cell Exhaustion During Persistent Viral Infection Is Regulated Independently of the Virus-Specific T Cell Receptor
    Jackson SR, Berrien-Elliott MM, Meyer JM, Wherry EJ, Teague RM
    Immunol Invest 2013;42(3):204-20
  • Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance
    Berrien-Elliott MM, Jackson SR, Meyer JM, Rouskey CJ, Nguyen TL, Yagita H, Greenberg PD, DiPaolo RJ, Teague RM
    Cancer Res 2013 Jan 15;73(2):605-16

Invited Publications